Rezdiffra (resmetirom)

Rezdiffra (resmetirom) is the first FDA-approved medication for adults with metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) who have moderate to advanced liver scarring (fibrosis), used alongside diet and exercise to reduce liver fat, inflammation, and scarring by targeting liver thyroid hormone receptors. It’s an oral tablet taken once daily and works as a liver-directed therapy, though potential side effects include diarrhea, nausea, itching, and gallbladder issues, with ongoing studies confirming its long-term benefits.